{"mainPropery":{"diseaseId":5877,"diseaseName":"B-cell lymphoma","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/5877/b-cell-lymphoma","synonyms":["Lymphoma, B-Cell"],"synonyms-with-source":[{"name":"Lymphoma, B-Cell"}],"identifiers":[{"identifierType":"UMLS","identifierId":"C0079731"}]},"diseaseCategories":[{"diseaseTypeId":1,"diseaseTypeName":"Rare Cancers"}],"organizations":[{"resourceID":570,"resourceName":"Leukemia and Lymphoma Society","abbreviation":"","address1":"3 International Drive, Suite 200","address2":"","address3":"","address4":"","address5":"","city":"Rye Brook","state":"NY","zip":"10573","country":"United States","phone":"1-(888) 557-7177 (general)","tty":"","tollFree":"1-(800) 955-4572 (patients and families)","fax":"","email":"https://www.lls.org/content/contact-us","url":"https://www.lls.org/","freeText":""}],"resource descriptions":[{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/pubmed?term=B-cell%20lymphoma%5Btitle%5D%20AND%20hasabstract%5Btext%5D&cmd=DetailsSearch' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss B-cell lymphoma. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":9,"resourceId":12,"resourceName":"ClinicalTrials.gov","descriptionText":"<a href='http://www.clinicaltrials.gov/ct2/results?cond=%22B-cell+lymphomas%22' target='_blank'>ClinicalTrials.gov</a> lists trials that are related to B-cell lymphoma. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies. <br />\r\n<br />\r\n<em><strong>Please note:</strong>&nbsp;Studies listed on the&nbsp;ClinicalTrials.gov&nbsp;website are listed for informational purposes only; being listed does not reflect an endorsement by GARD or the NIH. We strongly recommend that you talk with a trusted healthcare provider before choosing to participate in any clinical study.</em>","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":102,"resourceId":120,"resourceName":"American Cancer Society","descriptionText":"The <a href='http://www.cancer.org/cancer/non-hodgkinlymphoma/detailedguide/non-hodgkin-lymphoma-what-is-non-hodgkin-lymphoma' target='_blank'>American Cancer Society</a> provides information on B-cell lymphoma. Please click on the link to access this resource.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":775,"resourceId":1860,"resourceName":"Mayo Clinic","descriptionText":"<a href='http://www.mayoclinic.org/diseases-conditions/non-hodgkins-lymphoma/basics/definition/con-20027792' target='_blank'>Mayo Clinic</a> has an information page on B-cell lymphoma.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1529,"resourceId":2128,"resourceName":"MedlinePlus","descriptionText":"<a href='https://www.nlm.nih.gov/medlineplus/lymphoma.html' target='_blank'>MedlinePlus</a> was designed by the National Library of Medicine to help you research your health questions, and it provides more information about this topic.\r\n<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1531,"resourceId":2162,"resourceName":"Medscape Reference","descriptionText":"<a href='http://emedicine.medscape.com/article/202677-overview' target='_blank'>Medscape Reference</a> provides information on this topic. You may need to register to view the medical textbook, but registration is free.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1543,"resourceId":2171,"resourceName":"National Cancer Institute","descriptionText":"The <a href='http://www.cancer.gov/types/lymphoma' target='_blank'>National Cancer Institute</a> provides the most current information on cancer for patients, health professionals, and the general public.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/DOID:707' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"}],"overviewQuestion":{"questionId":9936,"questionText":"What is B-cell lymphoma?","answerText":"<strong>B-cell lymphoma</strong>&nbsp;refers to&nbsp;types of <a href=\"http://www.mayoclinic.org/diseases-conditions/non-hodgkins-lymphoma/basics/definition/con-20027792\" target=\"_blank\">non-Hodgkin lymphoma</a> that&nbsp;are characterized by abnormalities of the \"B-cells\" (a type of white blood cell that makes <a href=\"http://www.cancer.gov/publications/dictionaries/cancer-terms?CdrID=44918\" tabindex=\"-1\" target=\"_blank\">antibodies</a> to help fight infection). The condition may grow and spread slowly with few symptoms (also known as indolent lymphoma) or may be very aggressive with severe symptoms. When present, signs and symptoms may include <a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/003097.htm\" tabindex=\"-1\" target=\"_blank\">swollen lymph nodes</a> in the neck, armpit, or groin; abdominal pain; fatigue; fever; night sweats; and/or weight loss. The underlying cause of B-cell lymphoma is poorly understood. However, the condition can be associated with genetic abnormalities, environmental factors, viruses, immunodeficiency states, and <a href=\"https://www.nlm.nih.gov/medlineplus/connectivetissuedisorders.html\" tabindex=\"-1\" target=\"_blank\">connective-tissue disorders</a>. <a href=\"http://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq#section/_190\" tabindex=\"-1\" target=\"_blank\">Treatment</a> is based on many factors, including the severity of the condition and the associated signs and symptoms.[10375][10376][10377]","dateModified":"2016-01-10T14:42:00"},"basicQuestions":[],"references":[],"relatedDiseases":[{"relatedDiseaseId":11955,"relatedDiseaseName":"Lymphoma","relation":"Parent","isRare":false,"hasGardPage":false},{"relatedDiseaseId":12125,"relatedDiseaseName":"Plasmablastic lymphoma","relation":"Child","isRare":true,"hasGardPage":true}],"gardCases":[],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[],"medicalProducts":[{"productId":236,"genericName":"Tositumomab and iodine I 131 tositumomab","tradeName":"Bexxar®","tradeLink":"http://us.gsk.com/products/assets/us_bexxar.pdf","manufacturer":"","sponsor":"GlaxoSmithKline","indication":"Treatment of patients with CD20 positive, follicular, non-Hodgkin's lymphoma, with and without transformation, whose disease is refractory to Rituximab and has relapsed following chemotherapy","drugInformationLink":"http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=Bexxar","medlinePlusLink":"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a609013.html"},{"productId":724,"genericName":"Pembrolizumab","tradeName":"Keytruda","tradeLink":"https://www.keytruda.com/primary-mediastinal-b-cell-lymphoma/","manufacturer":"","sponsor":"Merck, Sharp & Dohme Corp.","indication":"June 2018 approved for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/name/keytruda","medlinePlusLink":"https://medlineplus.gov/druginfo/meds/a614048.html"},{"productId":718,"genericName":"Tisagenlecleucel-T","tradeName":"Kymriah","tradeLink":"https://www.us.kymriah.com/diffuse-large-b-cell-lymphoma-adults/","manufacturer":"","sponsor":"Novartis Pharmaceuticals Corporation","indication":"May 2018,  KYMRIAH is a CD19-directed genetically modified autologous T-cell immunotherapy indicated for the treatment of patients with diffuse large B-cell lymphoma, high-grade B-cell lymphoma, or DLBCL arising from follicular lymphoma who received two or more lines of systemic therapy.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/name/kymriah","medlinePlusLink":"https://medlineplus.gov/druginfo/meds/a617053.html"},{"productId":193,"genericName":"Rituximab","tradeName":"Rituxan® (injection)","tradeLink":"http://www.gene.com/gene/products/information/oncology/rituxan/index.html","manufacturer":"","sponsor":"Genentech, Inc.","indication":"Treatment of non-Hodgkin's B-cell lymphoma.","drugInformationLink":"http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=Rituxan","medlinePlusLink":"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a607038.html"},{"productId":643,"genericName":"Venetoclax","tradeName":"Venclexta","tradeLink":"https://www.venclexta.com/","manufacturer":"","sponsor":"AbbVie Inc.","indication":"June 2018, venetoclax (Venclexta) received expanded approval for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/name/venclexta","medlinePlusLink":"https://medlineplus.gov/druginfo/meds/a616028.html"},{"productId":91,"genericName":"Ibritumomab tiuxetan","tradeName":"Zevalin","tradeLink":"http://www.zevalin.com/","manufacturer":"","sponsor":"Cell Therapeutics, Inc.","indication":"Treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, including patients with Rituximab (Rituxan) refractory follicular non-Hodgkin's lymphoma.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/name/zevalin","medlinePlusLink":"https://medlineplus.gov/druginfo/meds/a609012.html"},{"productId":604,"genericName":"idelalisib","tradeName":"Zydelig","tradeLink":"http://www.zydelig.com/","manufacturer":"","sponsor":"Gilead Sciences, Inc","indication":"(1) Relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities; and (2) Relapsed small lymphocytic lymphoma (SLL) in patients who have received at least two prior systemic therapies; and (3) Relapsed follicular B-cell non-Hodgkin lymphoma (FL) in patients who have received at least two prior systemic therapies.","drugInformationLink":"http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=ZYDELIG","medlinePlusLink":""}],"EncodedName":"B-cell_lymphoma"}